J Am Heart Assoc:鲁塞格列净对糖尿病患者保留射血分数的心力衰竭的影响

2021-06-30 MedSci原创 MedSci原创

既往随机对照试验报道了钠-葡萄糖共转运体2抑制剂对减少心力衰竭住院的影响,但它们对射血分数保留的心力衰竭(HFpEF)患者的影响尚不清楚。近日,一项多中心、开放标签、随机对照试验评估了钠-葡萄糖共转运

既往随机对照试验报道了钠-葡萄糖共转运体2抑制剂对减少心力衰竭住院的影响,但它们对射血分数保留的心力衰竭(HFpEF)患者的影响尚不清楚。近日,一项多中心、开放标签、随机对照试验评估了钠-葡萄糖共转运体2抑制剂鲁塞格列净对2型糖尿病和HFpEF患者的药物疗效,研究结果已发表于J Am Heart Assoc。

研究纳入HFpEF(左心室射血分数>45%,BNP[B型钠尿肽]浓度≥35 pg/mL)的2型糖尿病患者,1:1随机分组分别接受鲁塞格列净 2.5 mg每日一次和伏格列波糖 0.2 mg每日三次。主要结果是2种药物治疗12周后BNP水平与基线的差异。

 

共纳入173名糖尿病的HFpEF患者,其中83名患者接受鲁塞格列净,82名患者接受伏格列波糖。两组患者在12周后BNP浓度相对基线下降方面没有显著差异。鲁塞格列净组第12周的平均BNP值与基线值之比为0.79,伏格列波糖组为0.87(变化百分比,-9.0% vs. -1.9%;鲁塞格列净与伏格列波糖的变化比为0.93;95%CI,0.78-1.10;P=0.26)。

综上,在2型糖尿病和HFpEF患者中,鲁塞格列净和伏格列波糖在12周后BNP浓度的降低程度方面没有显著差异。

 

原始出处:

 

Kentaro Ejiri, et al., Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. J Am Heart Assoc. 2020 Aug 18;9(16):e015103. doi: 10.1161/JAHA.119.015103. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1716184, encodeId=f0de1e161845b, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Tue Jul 13 22:30:36 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002172, encodeId=b50f10021e2bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90915537372, createdName=27274, createdTime=Sat Jul 24 09:30:36 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357730, encodeId=1c7b135e7300e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475096, encodeId=cf9714e5096db, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563479, encodeId=e45d15634e929, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978116, encodeId=ccd89e8116e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Wed Jun 30 08:43:35 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043675, encodeId=404310436e512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 30 03:30:36 CST 2021, time=2021-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1716184, encodeId=f0de1e161845b, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Tue Jul 13 22:30:36 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002172, encodeId=b50f10021e2bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90915537372, createdName=27274, createdTime=Sat Jul 24 09:30:36 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357730, encodeId=1c7b135e7300e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475096, encodeId=cf9714e5096db, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563479, encodeId=e45d15634e929, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978116, encodeId=ccd89e8116e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Wed Jun 30 08:43:35 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043675, encodeId=404310436e512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 30 03:30:36 CST 2021, time=2021-06-30, status=1, ipAttribution=)]
    2021-07-24 27274

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1716184, encodeId=f0de1e161845b, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Tue Jul 13 22:30:36 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002172, encodeId=b50f10021e2bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90915537372, createdName=27274, createdTime=Sat Jul 24 09:30:36 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357730, encodeId=1c7b135e7300e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475096, encodeId=cf9714e5096db, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563479, encodeId=e45d15634e929, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978116, encodeId=ccd89e8116e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Wed Jun 30 08:43:35 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043675, encodeId=404310436e512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 30 03:30:36 CST 2021, time=2021-06-30, status=1, ipAttribution=)]
    2021-07-01 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1716184, encodeId=f0de1e161845b, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Tue Jul 13 22:30:36 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002172, encodeId=b50f10021e2bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90915537372, createdName=27274, createdTime=Sat Jul 24 09:30:36 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357730, encodeId=1c7b135e7300e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475096, encodeId=cf9714e5096db, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563479, encodeId=e45d15634e929, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978116, encodeId=ccd89e8116e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Wed Jun 30 08:43:35 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043675, encodeId=404310436e512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 30 03:30:36 CST 2021, time=2021-06-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1716184, encodeId=f0de1e161845b, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Tue Jul 13 22:30:36 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002172, encodeId=b50f10021e2bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90915537372, createdName=27274, createdTime=Sat Jul 24 09:30:36 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357730, encodeId=1c7b135e7300e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475096, encodeId=cf9714e5096db, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563479, encodeId=e45d15634e929, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978116, encodeId=ccd89e8116e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Wed Jun 30 08:43:35 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043675, encodeId=404310436e512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 30 03:30:36 CST 2021, time=2021-06-30, status=1, ipAttribution=)]
    2021-07-01 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1716184, encodeId=f0de1e161845b, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Tue Jul 13 22:30:36 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002172, encodeId=b50f10021e2bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90915537372, createdName=27274, createdTime=Sat Jul 24 09:30:36 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357730, encodeId=1c7b135e7300e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475096, encodeId=cf9714e5096db, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563479, encodeId=e45d15634e929, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978116, encodeId=ccd89e8116e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Wed Jun 30 08:43:35 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043675, encodeId=404310436e512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 30 03:30:36 CST 2021, time=2021-06-30, status=1, ipAttribution=)]
    2021-06-30 14758c02m67暂无昵称

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1716184, encodeId=f0de1e161845b, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Tue Jul 13 22:30:36 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002172, encodeId=b50f10021e2bd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90915537372, createdName=27274, createdTime=Sat Jul 24 09:30:36 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357730, encodeId=1c7b135e7300e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475096, encodeId=cf9714e5096db, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563479, encodeId=e45d15634e929, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jul 01 15:30:36 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978116, encodeId=ccd89e8116e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fe45209642, createdName=14758c02m67暂无昵称, createdTime=Wed Jun 30 08:43:35 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043675, encodeId=404310436e512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 30 03:30:36 CST 2021, time=2021-06-30, status=1, ipAttribution=)]
    2021-06-30 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

ESC heart Failure:心力衰竭患者的患癌风险更高!

心力衰竭影响全球大约 6500 万人。尽管有创新的治疗方法,但心力衰竭患者的死亡率仍然高得令人无法接受。心力衰竭患者的预后和生活质量在很大程度上受到其他多种合并症的影响。

JACC:miR-132,预防肥厚性心肌病心衰进展的有效靶点!

miR-132,预防肥厚性心肌病心衰进展的有效靶点!

Heart:心力衰竭诊断中利钠肽水平及其与住院和死亡风险的关系

基线较高的NP水平与HF相关住院率增加和生存率降低相关。

ESC Heart Failure:心力衰竭患者患癌风险更高!

近年来,随着我国生活水平逐渐提高以及人口老龄化到来,高血压、冠心病、糖尿病、老年瓣膜病等心血管疾病患病率也在逐年增长,而心力衰竭作为各种心血管病后期综合症,已成为社会广泛关注的焦点问题。

Am Heart J: 心力衰竭和射血分数降低的患者使用恩加列净治疗12周的情况

目前,一种常用的SGLT2抑制剂恩加列净是否能降低NT-proBNP并改善无T2D的HFrEF患者的临床HF结局尚不清楚。近日,一项随机安慰剂对照试验中,研究人员探究了钠-葡萄糖协同转运体-2抑制剂恩

Eur J Heart Fail:奥美拉唑在射血分数降低的慢性心力衰竭患者中的应用

GALACTIC-HF试验正在测试新型选择性心脏肌球蛋白激活剂omecamtiv mecarbil在射血分数降低的心力衰竭(HFrEF)患者中的安全性和有效性。本研究中,研究人员描述了GALACTIC